Wise P, Drury M
Royal College of General Practitioners, London.
BMJ. 1996 Nov 16;313(7067):1245-8. doi: 10.1136/bmj.313.7067.1245.
To assess the outcome of 100 general practice based, multicentre research projects submitted to the ethics committee of the Royal College of General Practitioners by pharmaceutical companies or their agents between 1984 and 1989.
Analysis of consecutive submitted protocols for stated objectives, study design, and outcomes; detailed review of committee minutes and correspondence in relation to amendment and approval; assessment of final reports submitted at conclusion of studies.
82 finally approved protocols, embracing 34,523 proposed trial subjects and 1195 proposed general practice investigators.
Success at enrolling subjects and investigators; commencement and completion data; validity of final report's assessment of efficacy, safety, tolerability, and acceptability; and method of use and dissemination of findings.
18 studies were not approved and 45 had to be amended. Randomised controlled trials comprised 46 of the original submissions. Remuneration considerations, inadequate information or consent sheets, pregnancy safety, the need to discontinue existing therapy, and suboptimal scientific content were major reasons for rejecting studies or asking for amendments. Of the 82 approved studies 8 were not started. Shortfalls of investigators (of 39%) and trial subjects (of 37%) and an overall 23% withdrawal rate were responsible for a significant incidence of inconclusive results. Within the six year follow up interval, only 19 of the studies had been formally published.
This audit identified substantial ethical concerns in the process of approving multicentre general practice pharmaceutical research.
评估1984年至1989年间制药公司或其代理商提交给皇家全科医师学院伦理委员会的100个基于全科医疗的多中心研究项目的结果。
对提交的连续方案进行分析,包括既定目标、研究设计和结果;详细审查委员会会议记录以及与修订和批准相关的信函;评估研究结束时提交的最终报告。
82个最终获批的方案,涉及34523名拟招募的试验对象和1195名拟参与的全科医疗研究者。
招募对象和研究者的成功率;启动和完成数据;最终报告对疗效、安全性、耐受性和可接受性评估的有效性;研究结果的使用和传播方法。
18项研究未获批准,45项研究需要修订。最初提交的方案中46项为随机对照试验。报酬考量、信息或同意书不充分、妊娠安全性、停用现有治疗的必要性以及科学内容欠佳是拒绝研究或要求修订的主要原因。在82项获批研究中,8项未启动。研究者短缺(占39%)、试验对象短缺(占37%)以及总体23%的退出率导致了大量无结论性结果的出现。在六年的随访期内,只有19项研究正式发表。
本次审核发现多中心全科医疗药物研究审批过程中存在重大伦理问题。